Loading...
•
Dec 31, 2020
Bausch Health Q4 2020 Earnings Report
Bausch Health announced an agreement with Carl C. Icahn, appointing two new directors to the board and securing Icahn's support for all Bausch Health nominees at the 2021 Annual Meeting.
Key Takeaways
Bausch Health reached an agreement with the Icahn Group, appointing Brett Icahn and Steven Miller as new independent directors to the Board, effective mid-March 2021. The Icahn Group, owning approximately 7.83% of the Company’s outstanding common stock, agreed to vote in favor of the Board’s nominees at the 2021 Annual Meeting.
Two new independent directors, Brett Icahn and Steven Miller, will be appointed to Bausch Health's Board in mid-March 2021.
The Icahn Group, holding approximately 7.83% of Bausch Health's common stock, will support all Bausch Health nominees at the 2021 Annual Meeting.
The new directors will serve on the Finance and Transactions Committee and the committee assisting with evaluating strategic alternatives, including the potential spin-off of the eye health business.
The agreement aims to unlock unrecognized value in Bausch Health and build on progress in capitalizing on areas of unmet medical need and gaining market share.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...